NCT03966651 - A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Neuroblastoma

Interventions

DRUG

PRRT with 177Lu-DOTATATE

Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.

Trial Locations (14)

RECRUITING

CHU Angers, Angers

RECRUITING

CHU Besançon, Besançon

RECRUITING

CHU Pellegrin, Bordeaux

RECRUITING

CHU Dijon, Dijon

RECRUITING

CHU de Grenoble, Grenoble

RECRUITING

Centre Oscar Lambret, Lille

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

Hopital Arnaud de Villeneuve, Montpellier

RECRUITING

CHU Nancy, Nancy

RECRUITING

CHU Nantes, Nantes

RECRUITING

CHU Reims, Reims

RECRUITING

CHU Strasbourg, Strasbourg

RECRUITING

CHU de Toulouse - Hôpital des enfants, Toulouse

RECRUITING

IUCT-O, Toulouse